Biomedical and NC Biomatrix Sign Memorandum of Understanding

Biomedical, the unrivaled expert in biomaterial science aiming to solve the world’s healthcare needs through sustainable science, and NC Biomatrix, a Dutch-based medical device startup, have signed a Memorandum of Understanding for the development of breakthrough regenerative devices for the treatment of back pain. 

NC Biomatrix‘s most advanced technology is VitaDisc, a proprietary treatment of degenerative disc disease that affects the spine, and is pending expected regulatory approval. The agreement with Biomedical will support a subsequent scaling up of manufacturing to market demand in the future, and will also serve as the catalyst for the development of similar technologies for other unmet clinical needs.

Bob Guilleaume, CEO of NC Biomatrix commented: “We are thrilled, of course, to begin a partnership with Biomedical – a world leader in biomaterials for medical use. NC Biomatrix will greatly profit from the competence and experience of dsm-firmenich in the area of biomaterial manufacturing and development, in addition to the dsm-firmenich network that will help us to address the US market.”

Furthermore, Biomedical and Biomatrix’s Dr. Keita Ito - Chief Science Officer of NC Biomatrix and developer of VitaDisc - having worked together in varying capacities, have a deep respect and appreciation for their shared competencies when it comes to solving medical challenges.

Frank Yohe, Director of Biomaterials – Natural Materials at Biomedical, stated that: “We look forward to partnering with NC Biomatrix, contributing Biomedical's biomaterials leadership and expertise towards the commercialization of VitaDisc and other regenerative devices. VitaDisc has the potential to transform the treatment of such a debilitating disease and vastly improve patient outcomes, which ultimately supports our worldwide vision of solving the world's healthcare needs through sustainable science.”

The signing of the Memorandum of Understanding is the foundation for entering into a Supply Agreement, as well as potential Development Agreement for future NC Biomatrix products. Both teams are excited to continue their partnership, as they focus on significantly improving patient outcomes across the globe for many years to come.